Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Multiplex proteomics could improve understanding and risk prediction of major adverse cardiovascular events (MACE) in type 2 diabetes. This study assessed 80 cardiovascular and inflammatory proteins for biomarker discovery and prediction of MACE in type 2 diabetes. METHODS: We combined data from six prospective epidemiological studies of 30-77-year-old individuals with type 2 diabetes in whom 80 circulating proteins were measured by proximity extension assay. Multivariable-adjusted Cox regression was used in a discovery/replication design to identify biomarkers for incident MACE. We used gradient-boosted machine learning and lasso regularised Cox regression in a random 75% training subsample to assess whether adding proteins to risk factors included in the Swedish National Diabetes Register risk model would improve the prediction of MACE in the separate 25% test subsample. RESULTS: Of 1211 adults with type 2 diabetes (32% women), 211 experienced a MACE over a mean (±SD) of 6.4 ± 2.3 years. We replicated associations (<5% false discovery rate) between risk of MACE and eight proteins: matrix metalloproteinase (MMP)-12, IL-27 subunit α (IL-27a), kidney injury molecule (KIM)-1, fibroblast growth factor (FGF)-23, protein S100-A12, TNF receptor (TNFR)-1, TNFR-2 and TNF-related apoptosis-inducing ligand receptor (TRAIL-R)2. Addition of the 80-protein assay to established risk factors improved discrimination in the separate test sample from 0.686 (95% CI 0.682, 0.689) to 0.748 (95% CI 0.746, 0.751). A sparse model of 20 added proteins achieved a C statistic of 0.747 (95% CI 0.653, 0.842) in the test sample. CONCLUSIONS/INTERPRETATION: We identified eight protein biomarkers, four of which are novel, for risk of MACE in community residents with type 2 diabetes, and found improved risk prediction by combining multiplex proteomics with an established risk model. Multiprotein arrays could be useful in identifying individuals with type 2 diabetes who are at highest risk of a cardiovascular event.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604304 · Cited by 743
Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes
on behalf of the SUMMIT Investigators, Looker, H. C., Colombo, M., Agakov, F., Zeller, T., Groop, L., Thorand, B., Palmer, C. N., Hamsten, A., de Faire, U., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3535-6 · Cited by 66
Cited by
Cai, Y., Cai, Y.-Q., Tang, L.-Y., Wang, Y.-H., Gong, M., Jing, T.-C., Li, H.-J., Li-Ling, J., Hu, W., Yin, Z., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03273-7 · Cited by 122
Kee, O. T., Harun, H., Mustafa, N., Abdul Murad, N. A., Chin, S. F., Jaafar, R., & Abdullah, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01741-7 · Cited by 82
“The sample size varies significantly among the prediction models discussed in this review, ranging from 560 in the study by Nowak and Carlsson [34] to more than 200,000 subjects in the study by Dworzynski, Aasbrenn [32].”
MethodChu, H., Chen, L., Yang, X., Qiu, X., Qiao, Z., Song, X., Zhao, E., Zhou, J., Zhang, W., Mehmood, A., et al. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.645418 · Cited by 40
Cardiovascular risk in patients with type 2 diabetes: A systematic review of prediction models
Galbete, A., Tamayo, I., Librero, J., Enguita-Germán, M., Cambra, K., & Ibáñez-Beroiz, B. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109089 · Cited by 32
Metadata
- Authors
- Nowak, C., Carlsson, A. C., Östgren, C. J., Nyström, F. H., Alam, M., Feldreich, T., Sundström, J., Carrero, J.-J., Leppert, J., Hedberg, P., Henriksen, E., Cordeiro, A. C., Giedraitis, V., Lind, L., Ingelsson, E., Fall, T., & Ärnlöv, J.
- Venue
- Diabetologia
- Published
- 2018-05-24
- Volume
- 61
- Issue
- 8
- Pages
- 1748-1757
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2804216646
- Cited by
- 65
- References
- 5
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes. https://app.cochat.ai/papers/10.1007/s00125-018-4641-z
- The paper
- Nowak, C., Carlsson, A. C., Östgren, C. J., Nyström, F. H., Alam, M., Feldreich, T., Sundström, J., Carrero, J.-J., Leppert, J., Hedberg, P., Henriksen, E., Cordeiro, A. C., Giedraitis, V., Lind, L., Ingelsson, E., Fall, T., & Ärnlöv, J. (2018). Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes. Diabetologia. https://doi.org/10.1007/s00125-018-4641-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.